SSRI use in pregnancy: Evaluating the risks and benefits

被引：0
|
作者：
du Toit, E. [1 ]
Thomas, E. [2 ,3 ]
Koen, L. [2 ,3 ]
Vythilingum, B. [4 ]
Grobler, S. [5 ]
Smith, N. [5 ]
Niehaus, D. [2 ,3 ]
机构：
[1] Sophia Clin, Cape Town, South Africa
[2] Univ Stellenbosch, Maternal Mental Hlth Clin, Stikland Hosp, Cape Town, South Africa
[3] Univ Stellenbosch, Dept Psychiat, Fac Med & Hlth Sci, Cape Town, South Africa
[4] Univ Cape Town, Dept Psychiat, Fac Hlth Sci, ZA-7700 Rondebosch, South Africa
[5] Walter Sisulu Univ, Dept Psychiat, Fac Hlth Sci, Mthatha, South Africa
来源：
SOUTH AFRICAN JOURNAL OF PSYCHIATRY | 2015年 / 21卷 / 02期
关键词：
SEROTONIN REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; IN-UTERO EXPOSURE; ALCOHOL SPECTRUM DISORDERS; ANTIDEPRESSANT USE; MATERNAL USE; INTERPERSONAL PSYCHOTHERAPY; ANTENATAL DEPRESSION; PRENATAL EXPOSURE; MAJOR DEPRESSION;
D O I：
10.7196/SAJP.587
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary pharmacological treatment for moderate to severe depression during pregnancy. Data regarding the safety of their use during pregnancy remain controversial and conflicting. Decisions regarding the prescription of antidepressant treatment are often fraught with concern around potential harmful medication effects on the pregnancy, fetus and infant. Information on potential risks remains extremely varied and inconsistent across sources. This lack of clarity regarding drug safety brings significant uncertainty not only for treating physicians, but also for women seeking information about depression during pregnancy. This review aims to summarise and evaluate the current evidence base and to aid clinicians in performing a risk/benefit analysis for SSRI use during pregnancy and lactation.
引用
收藏
页码：48 / 53
页数：6
相关论文
共 50 条
12345